The combination of ATR inhibitors with DNA TOP1 inhibitors was found to augment their antitumor efficacy and potentially improve the response to immunotherapy in SCLC characterized by low expression of the STING pathway [101, 128]. This evidence concerns the gene STING1 and small cell lung carcinoma.